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Abstract 
 
In the left ventricular assist device (LVAD) population, right ventricular (RV) failure 
represents a significant cause of morbidity and mortality. It is unclear whether 
hemodynamic monitoring with the implantable CardioMEMS system can improve 
outcomes within this population. This case report highlights two patients in our 
clinic who had CardioMEMS implanted after LVAD, enabling us to modify their 
medical regimens remotely and more frequently in the management of their RV 
failure.  
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Introduction 
LVADs remain an important therapy for end stage heart failure, exceeding the 
number of transplants performed annually in the US (1). However, despite the 
excellent results, early and/or progressive decline of right ventricular function after 
LVAD implant remain as major problems. These conditions have been shown to 
be associated with increased morbidity and mortality within the high-risk LVAD 
population (2). 
Previous studies have shown that CardioMEMS (St. Jude Medical, Inc.) 
hemodynamic monitoring affords several advantages in LVAD patients, reducing 
the number and duration of hospitalizations (3-5). This case report highlights the 
role of CardioMEMS in the management of patients who developed severe right 
heart failure after LVAD implantation. Both of these patients met the criteria for 
LVAD implantation, with severe symptoms despite optimal medical therapy. 
Case Study 1:  
The patient is a 75 year-old male aerospace engineer who presented with 
shortness of breath on exertion, ankle swelling, atrial fibrillation, low ejection 
fraction, Stage D heart failure status post biventricular implantable cardioverter 
defibrillator (ICD). His past medical history included ischemic heart disease, 
coronary artery bypass graft (CABG) and percutaneous coronary intervention 
(PCI). His symptoms gradually progressed to syncopal episodes, ventricular 
fibrillation requiring pacing, and New York Heart Association (NYHA) Class IV 
heart failure. In October 2016, a right heart catheterization demonstrated a low 
cardiac output of 2.2 L/min. The patient was admitted, placed on inotropic support, 
and evaluated for LVAD placement. Echocardiogram showed severe left 
ventricular dilatation with ejection fraction less than 20%, right ventricular 
dilatation, severe mitral regurgitation, severe aortic regurgitation, and mild tricuspid 
regurgitation. (Video 1. Echo of patient 1.  https://imgur.com/a/uArwoFH). 
During his hospital stay, the patient was selected for LVAD destination therapy and 
a HeartMate II LVAD was implanted with aortic valve closure on November 16, 
2016. His hospitalization was complicated by aspiration pneumonitis as well as 
episodes of ventricular tachycardia, possibly due to dual inotropic support. He 
underwent extensive physical and occupational therapy, and was discharged on 
December 2, 2016 with LVAD pump speed 8600 rotations per minute (rpm), 
bumetanide 1.5mg daily and spironolactone 50mg daily.  
The patient developed worsening right heart failure symptoms in the following 
weeks, including dyspnea on exertion, lower extremity edema and weight gain. 
Patient was readmitted to the hospital on April 12, 2017 and was considered as a 
candidate for CardioMEMS hemodynamic monitoring. The CardioMEMS was 
implanted on May 1, 2017. He was admitted to the ICU after developing post-
procedural hemoptysis due to pulmonary artery perforation and left lung collapse 
requiring intubation. The procedure required stiffer wires during intervention due to 
complex anatomy, which may have prompted the hemoptysis. The patient was 
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also on aspirin 325 mg daily and Plavix 75 mg. He was discharged on May 11, 
2017 with LVAD pump speed 9000 rpm, bumetanide 1mg daily and spironolactone 
25mg daily based on hemodynamic monitoring.  
 
 
 
Figure 1. Patient 1 CardioMEMS Data with Bumetanide Dosage 
 
CardioMEMS measurements were transmitted three times a week to the 
cardiology team to monitor pulmonary artery diastolic pressure (PADP) (Figure 1). 
Bumetanide dosage adjustments based on CardioMEMS were communicated to 
the patient over telephone with the goal of lowering PADP. On September 1, 2017, 
a follow-up right heart catheterization was performed and showed continued 
volume overload with pulmonary capillary wedge pressure (PCWP) 23 mmHg 
(Table 1). LVAD pump speed was increased from 9000rpm to 9400rpm in order to 
increase cardiac index. 
CardioMEMS-directed management was continued and bumetanide dosage was 
reduced to 3mg twice per day (bid). Patient showed clinical improvement in 
physical stamina and quality of life without dyspnea on exertion or lower extremity 
edema despite echocardiogram showing continued severe right ventricular systolic 
dysfunction. (Video 2. Patient 1. Severe right ventricular dysfunction.  
https://imgur.com/TazuX9N ) Patient’s visits have decreased in frequency to less 
than once per month, he has had no hospitalizations, and he continues to work.  
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Table 1. Patient 1 Cardiac Catheterization Data 
 Before LVAD After LVAD After CardioMEMS 
Date 10/31/2016 5/1/2017 9/1/2017 
RAP (mmHg) 21 19  10  
PAP (mmHg) Systolic/Diastolic 
(Mean) 
65/34 (44) 55/28 (38)  41/15 (26)  
PCWP (mmHg) 35 32  23  
CI 1.1 1.78  1.90  
 
RAP right atrial pressure 
PAP pulmonary arterial pressure 
PCWP – pulmonary capillary wedge pressure 
CI – cardiac index 
 
Case Study 2:  
The patient is a 76 year-old male who presented to the clinic with shortness of 
breath on exertion, bilateral leg edema, orthopnea, paroxysmal nocturnal dyspnea, 
and fatigue. His history was significant for Stage C, NYHA Class III to IV non-
ischemic cardiomyopathy with ejection fraction of 25%. He also had hypertension, 
hyperlipidemia, diabetes mellitus, paroxysmal atrial fibrillation with biventricular 
ICD, and chronic renal insufficiency. His symptoms progressed despite optimal 
medical therapy and he was therefore considered a candidate for LVAD 
placement. Echocardiogram showed severe left ventricular dilatation with ejection 
fraction less than 20%, right ventricle dilatation, mild to moderate mitral 
regurgitation, and mild tricuspid regurgitation. 
The patient was selected for LVAD destination therapy and a HeartMate II LVAD 
was implanted on June 17, 2015. He underwent physical therapy and was 
discharged with LVAD pump speed 9000 rpm, bumetanide 1mg daily and 
spironolactone 25mg daily.  
His first year post-LVAD was mostly uneventful despite several falls without 
cardiac complications leading to distal fractures that required hospital admission 
for follow-up. However, symptoms gradually worsened with increased PI events, 
low-flow alarms on LVAD, declining right heart function, and 20 pounds of weight 
gain over 3 weeks in January 2017. Patient was admitted to the hospital for 
volume overload, renal dysfunction and worsening right side dysfunction on 
January 26, 2017 and considered as a candidate for CardioMEMS placement to 
optimize management of his treatment. The patient had CardioMEMS implanted 
on January 31, 2017 with an uneventful post-operative period.  
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Figure 2. Patient 2 CardioMEMS Data with Bumetanide Dosage 
 
CardioMEMS measurements were transmitted three times a week to the 
cardiology team and treatment adjustments were communicated to the patient 
over telephone. The patient became more symptomatic with shortness of breath, 
dyspnea on exertion, as well as weight gain despite the use of diuretics and dosing 
per his CardioMEMS reading. Therefore, the patient was scheduled for right heart 
catheterization on March 7, 2017 and admitted to the hospital following his 
catheterization due to significant volume overload. The patient had multiple ramp 
studies performed as well as RV pacing changed to LV pacing to help with septal 
wall motion due to concerns that the LVAD cannula may have been dislodged or 
moved towards the septum due to mechanical falls. He was discharged on March 
14, 2017 with LVAD pump speed 8600 rpm, bumetanide 2mg daily, spironolactone 
12.5mg every 48 hours. 
CardioMEMS-directed management was continued and bumetanide dosage was 
adjusted accordingly, decreasing from 7.5mg bid in October 2017 to 0.5mg daily in 
July 2018. Most recent catheterization showed RAP 3 mmHg, mean PAP 13 
mmHg, and CI 3.6 despite ongoing right ventricular dysfunction (Video 3. Ongoing 
right ventricular dysfunction in Case 2. https://imgur.com/a/f1p2j30). 
 Patient continues to follow up at our clinic regularly for all recommended visits. 
His hemodynamics is shown in Table 2. 
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Table 2. Patient 2 Cardiac Catheterization Data 
 Before LVAD After LVAD After CardioMEMS 
Date 6/9/2015 1/31/2017 10/18/2017 
RAP (mmHg) 10 12  18  
PAP (mmHg) Sys/Dia (Mean) 48/22 (32) 44/16 (33) 42/20 (31)  
PCWP (mmHg) 17 20 20  
CI 1.72 1.87 3.3 
 
Discussion:  
Right heart failure (RHF) is a frequent complication following LVAD implantation 
with an incidence of 20-50% of cases. RHF may lead to impaired LVAD flow, 
decreased tissue perfusion and multi-organ failure, which are associated with 
increased morbidity and mortality. Despite the fact that many risk factors 
contributing to the development of RHF after LVAD implantation have been 
identified, management of right ventricular dysfunction still remains a challenge. 
The functions of the left and right ventricles are intimately linked through systolic 
ventricular interaction due to sharing of oblique fibers in the interventricular septum 
(6). The oblique fibers determine shortening and lengthening that produces 80% of 
RV systolic function (7). Both ventricles are dependent on one another, thus any 
change in compliance, shape, or size of one ventricle can affect the other (8). 
After LVAD implantation, there is often loss of the septal contribution to overall RV 
function with postoperative paradoxical septal motion. Acute hypoxemia 
perioperatively can also result in pulmonary vasoconstriction, worsening 
pulmonary vascular resistance, and associated RV dysfunction. Over time, there is 
increased flow from the LV/LVAD and increased venous return to the RV, resulting 
in an increase in RV preload. These factors lead to worsening of right heart 
function both in early stages after LVAD implantation and progressively over 
months or years. 
The CardioMEMS pulmonary artery (PA) pressure monitor is a small implantable 
wireless sensor that is placed in a branch pulmonary artery for continuous 
monitoring of PA pressures. It has been shown to be safe, reliable and clinically 
effective in reducing HF associated hospitalizations for New York Heart 
Association (NYHA) Class III patients as described in the CHAMPION trial (9,10). 
CardioMEMS monitoring enables optimization of the balance between PA 
pressures and LV filling through controlling volume status with the use of diuretics 
in order to achieve required cardiac output. Keeping PA pressures low preserves 
RV function and helps prevent unfavorable irreversible cardiac remodeling (11). In 
a sense, keeping PA pressure low, but not too low, may mimic Fontan physiology 
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so that RV dysfunction becomes less important. If the pressures are too low, then 
LV filling may be insufficient to meet the demands of the LVAD pump. Thus 
diuretic dosing and LVAD pump speed are two key components of managing 
volume status in LVAD patients to avoid symptoms of heart failure and enable 
patients to attain better quality of life. 
In our first patient, we observe a dramatic decline in right atrial pressure, 
pulmonary artery pressure, and pulmonary capillary wedge pressure after 
CardioMEMS implant (Table 1). CardioMEMS pulmonary arterial diastolic pressure 
(PADP) trend data confirms our observations, particularly after LVAD pump speed 
increase to achieve higher cardiac index in September 2017 (Figure 1). Patient 1 
has had no additional hospitalizations since his implant, whether cardiac or non-
cardiac related (Table 3). He is currently achieving our goal PADP of 17mmHg 
through CardioMEMS-guided diuretic management and not experiencing any heart 
failure symptoms.  
Table 3. Patient Data with CardioMEMS after LVAD Implantation 
Patient and 
Device 
Months 
between 
LVAD 
implantation 
and 
CardioMEMS 
Months of 
data 
collection 
with 
CardioMEMS 
Number of HF-
related 
hospitalizations 
before 
CardioMEMS 
Number of HF-
related 
hospitalizations 
after 
CardioMEMS 
Number of 
diuretic 
adjustments 
with 
CardioMEMS 
Patient 1 – 
Heartmate II 
5 15 2 0 16 
Patient 2 – 
Heartmate II 
18 18 3 3 54 
 
Our second patient has unfortunately had multiple hospitalizations due to non-
cardiac related mechanical falls which have complicated our management 
strategy. However, we have been able to manage his right heart failure on an 
outpatient basis despite significant RV dysfunction. He had not yet shown a 
decline in right heart pressures at the time of his most recent catheterization 
(Table 2), but his most recent echocardiogram showed significant improvement 
with RAP 3 mmHg and mean PAP 13 mmHg. His cardiac index has increased 
from 1.87 to 3.6 and CardioMEMS monitoring has enabled us to make 54 diuretic 
adjustments since implant (Table 3), which would have been unfeasible without 
remote monitoring. He is currently taking 1.5mg bumetanide per day, compared to 
his dosage of 7.5mg bumetanide bid approximately 1 year ago, and achieving our 
goal PADP of 12mmHg (Figure 2). 
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Conclusion  
The benefit of CardioMEMS has not been adequately investigated in patients with 
LVAD and RV failure, a population which carries a high readmission rate after 
implantation. Review of our cases supports the use of CardioMEMS in 
management of right-sided heart failure with LVAD. Further work will be needed to 
definitively establish guidelines regarding the use of this dual device therapy.  
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